Focus Financial Network Inc. Boosts Holdings in Boston Scientific Co. (NYSE:BSX)

Focus Financial Network Inc. lifted its holdings in Boston Scientific Co. (NYSE:BSX) by 9.8% in the fourth quarter, HoldingsChannel reports. The fund owned 18,121 shares of the medical equipment provider’s stock after buying an additional 1,615 shares during the period. Focus Financial Network Inc.’s holdings in Boston Scientific were worth $1,619,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BSX. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in Boston Scientific by 9.7% in the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 119 shares during the last quarter. Adero Partners LLC increased its stake in shares of Boston Scientific by 3.3% in the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider’s stock worth $334,000 after buying an additional 120 shares during the period. Grove Bank & Trust raised its holdings in Boston Scientific by 4.4% during the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider’s stock valued at $261,000 after buying an additional 122 shares during the last quarter. PFG Investments LLC boosted its position in Boston Scientific by 1.6% during the 4th quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider’s stock valued at $725,000 after buying an additional 125 shares during the period. Finally, Stonegate Investment Group LLC grew its holdings in Boston Scientific by 1.6% in the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider’s stock worth $699,000 after acquiring an additional 126 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.1 %

Shares of BSX opened at $106.03 on Wednesday. The firm has a fifty day moving average price of $95.19 and a 200-day moving average price of $87.50. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $156.26 billion, a P/E ratio of 84.82, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 12-month low of $64.54 and a 12-month high of $107.17.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Equities research analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP John Bradley Sorenson sold 4,119 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig sold 4,877 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now directly owns 39,398 shares in the company, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,830 shares of company stock worth $5,149,969. 0.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. UBS Group upped their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Barclays upped their price target on Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Monday. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, January 29th. Citigroup boosted their target price on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, Canaccord Genuity Group raised their price target on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $107.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.